慢加急性肝衰竭的免疫治疗

Immunotherapy for acute-on-chronic liver failure

慢加急性肝衰竭(ACLF)是一种严重威胁生命的疾病,具有多器官衰竭、脓毒症和死亡的高风险。ACLF在体内激活先天免疫反应和获得性免疫反应,从而引起持续的全身炎症反应综合征和多器官功能障碍的发展,导致该病的高病死率。失调的免疫反应在疾病进展中起关键作用,免疫疗法可能有助于针对免疫介导的器官损伤,抑制肝衰竭的进展,就目前ACLF中具有潜在免疫调节作用的药物与手段的作用及其机制进行了综述,以期为ACLF的免疫治疗提供参考。

Acute-on-chronic liver failure(ACLF)is a life-threatening disease with a high risk of multiple organ failure,sepsis,and death.ACLF activates innate and acquired immune responses in human body and thus leads to the progression of persistent systemic inflammatory response syndrome and multiple organ dysfunction,leading to the high mortality rate of this disease.Dysregulated immune response plays a key role in disease progression,and immunotherapy may help to target immune-mediated organ damage and inhibit the progression of liver failure.This article reviews the role and mechanism of drugs and means with a potential immune regulatory effect in ACLF,in order to provide a reference for immunotherapy for ACLF.